Moreover, Licofelone showed a dose-dependent anticancer response by activation of apoptosis and reduction of the immune-resistant tumor cell population and proved to be more efficient than single COX-2 inhibition (celecoxib)80–82. This evidence concerns the gene PTGS2 and neoplasm.